Modified cell lines for increasing lentiviral titers
The present disclosure provides a method of modifying cells in order to enhance lentiviral titers, cell lines that are modified and modifying reagents. By mediating individual genes and combination thereof, lentiviral titers may be increased.
1. A method of enhancing lentiviral titers comprising modulating expression of a plurality of host genes in a packaging cell, wherein the modulation comprises”
a) suppressing expression of Tetherin, and
b) at least one of
i) suppressing expression of at least one of Dicer and DGCR8, and
ii) increasing expression of at least one of TSG101 and Anx2.
2. The method of claim 1 , wherein expression of Dicer is suppressed.
3. The method of claim 1 , wherein expression of DGCR8 is suppressed.
4. The method of claim 3 further comprising suppressing expression of Dicer.
5. The method of claim 1 , wherein expression of TSG101 is increased.
6. The method of claim 1 , wherein expression of Anx2 is increased.
7. The method of claim 6 further comprising increasing expression of TSG 101.
8. The method according to claim 1 , wherein said modulating expression of Tetherin comprises only partially suppressing Tetherin.
9. The method according to claim 8 , wherein the at least one gene is involved in an RNAi pathway.
10. The method according to claim 1 , wherein said modulating comprises expressing a first shRNA from an expression construct within the packaging cell, wherein the first shRNA inhibits Tetherin and expressing a second shRNA from the expression construct, wherein the second shRNA inhibits DGCR8.
11. The method according to claim 10 , wherein each of Tetherin and DGCR8 are only partially suppressed.
12. The method according to claim 1 , wherein said modulating comprises expressing an shRNA from an expression construct within the packaging cell, wherein the shRNA inhibits Tetherin, and causing overexpression of TSG101.
13. The method according to claim 12 , wherein Tetherin is only partially suppressed.
14. The method according to claim 13 , wherein TSG101 is overexpressed by at least 30%.
15. The method according to claim 14 , wherein Tetherin is suppressed by 30% to 40%.
16. The method according to claim 1 , wherein said modulating comprises expressing an shRNA from an expression construct within the packaging cell, wherein the shRNA inhibits Tetherin, and causing overexpression of Anx2.
17. The method according to claim 16 , wherein Tetherin is only partially suppressed.
18. The method according to claim 17 , wherein Anx2 is overexpressed by at least 30%.
19. The method according to claim 18 , wherein Tetherin is suppressed by 30% to 40%.